Lugano Financial Advisors SA (LFA)’s Novartis NVS Stock Holding History

Lugano Financial Advisors SA (LFA)’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-250	Closed	-$24.1K	–	195
2023 Q3	$24.1K	Hold	250	–	–	0.02%	130
2023 Q2	$25.2K	Buy	+250	New	+$25K	0.02%	149

Other funds holding NVS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lugano Financial Advisors SA (LFA)'s NVS Position: Q4 2023 in Review

Lugano Financial Advisors SA (LFA) sold out of Novartis (NVS) in Q4 2023, closing a stake of 250 shares — an estimated $24.1K sold.

Lugano Financial Advisors SA (LFA) first reported a position in NVS in Q2 2023 and held it in 2 quarters. The position peaked at $25.2K in Q2 2023. 1,272 funds tracked by Wall St. Rank hold NVS as of Q4 2023.

Lugano Financial Advisors SA (LFA) reported no remaining Novartis position as of Q4 2023 after selling out during the quarter.
Lugano Financial Advisors SA (LFA) sold 250 Novartis shares in Q4 2023, an estimated $24.1K.
Lugano Financial Advisors SA (LFA) first reported a position in Novartis in Q2 2023 and held it in 2 quarters.
Lugano Financial Advisors SA (LFA)'s Novartis position peaked at $25.2K in Q2 2023.
1,272 funds tracked by Wall St. Rank held Novartis as of Q4 2023.

Based on Lugano Financial Advisors SA (LFA)'s 13F filing for Q4 2023, filed 22 Jan 2024.